3151 - 3160 of 8654 Results
Title
Year
-
OPENTitle: Snca-GFP Knock-In Mice Reflect Patterns of Endogenous Expression and Pathological SeedingJournal Name: eneuroPublisher: Society for NeuroscienceVol: 7Issue #: 4Start Page: ENEURO.0007End Page: 20.2020Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1523/eneuro.0007-20.2020Best OA location URL: https://www.eneuro.org/content/eneuro/7/4/ENEURO.0007-20.2020.full.pdfCitation Count: 21
-
OPENTitle: Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 8Start Page: 1761End Page: 1767Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29124Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.29124Citation Count: 7
-
RESTRICTEDTitle: PPMI 2.O New Science/New Cohorts - Transforming PPMI (2490)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 94Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.94.15_supplement.2490Citation Count: 7
- Blood-Based Nanoparticle-Enhanced Quaking-Induced Conversion (Nano-QuIC): Inhibitor-Resistant Detection of Seeding Activity in Patients Diagnosed with Parkinson’s Disease2024RESTRICTEDTitle: Blood-Based Nanoparticle-Enhanced Quaking-Induced Conversion (Nano-QuIC): Inhibitor-Resistant Detection of Seeding Activity in Patients Diagnosed with Parkinson’s DiseaseJournal Name: Nano LettersPublisher: American Chemical Society (ACS)Vol: 24Issue #: 47Start Page: 15016End Page: 15024Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.nanolett.4c03768Citation Count: 4
- Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease2018OPENTitle: Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson diseaseJournal Name: Experimental NeurologyPublisher: Elsevier BVVol: 303Issue #:Start Page: 95End Page: 107Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.expneurol.2018.01.015Citation Count: 39
-
OPENTitle: Forecasts for the Attainment of Major Research Milestones in Parkinson’s DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 10Issue #: 3Start Page: 1047End Page: 1055Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3233/jpd-201933Best OA location URL: https://escholarship.mcgill.ca/concern/articles/5425kg39cCitation Count: 4
- Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial2024OPENTitle: Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trialJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 30Issue #: 9Start Page: 2631End Page: 2640Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41591-024-03101-8Best OA location URL: https://doi.org/10.1038/s41591-024-03101-8Citation Count: 16
- Reply: Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson’s disease and BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson’s disease2020OPENTitle: Reply: Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson’s disease and BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson’s diseaseJournal Name: BrainPublisher: Oxford University Press (OUP)Vol: 144Issue #: 2Start Page: e16End Page: e16Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1093/brain/awaa369Best OA location URL: https://academic.oup.com/brain/article-pdf/144/2/e16/36454303/awaa369.pdfCitation Count: 0
- The Experience of OFF Periods in Parkinson’s Disease: Descriptions, Triggers, and Alleviating Factors2021OPENTitle: The Experience of OFF Periods in Parkinson’s Disease: Descriptions, Triggers, and Alleviating FactorsJournal Name: Journal of Patient-Centered Research and ReviewsPublisher: Aurora Health Care, Inc.Vol: 8Issue #: 3Start Page: 232End Page: 238Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.17294/2330-0698.1836Best OA location URL: https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1836&context=jpcrrCitation Count: 13
-
RESTRICTEDTitle: The PRIPS study: screening battery for subjects at risk for Parkinson's diseaseJournal Name: European Journal of NeurologyPublisher: WileyVol: 20Issue #: 1Start Page: 102End Page: 108Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/j.1468-1331.2012.03798.xCitation Count: 119